Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026
MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ('Telomir' or the 'Company'), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions.
Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026.
As part of its expanding pipeline, Telomir is advancing a rare-disease exploratory and developmental strategy focused on high-need orphan indications where cellular aging plays a central role. These include:
The Company plans to meet with the FDA to establish novel clinical endpoints across its rare disease programs, aiming to unlock accelerated development pathways and regulatory flexibility.
In parallel, Telomir-1 is also being investigated in autism spectrum disorder, where its potential impact on telomere biology, oxidative stress, neurodegeneration and inflammation may offer a novel therapeutic approach for neurodevelopmental conditions.
Beyond rare and neurological disorders, Telomir has achieved significant preclinical success across a range of high-impact therapeutic areas, underscoring the versatility of its platform:
'The breadth of our preclinical data showcases the potential of Telomir-1 not just as a treatment-but as a platform for addressing aging-related and rare diseases at the source,' said Erez Aminov, Chief Executive Officer of Telomir. 'As we prepare for IND submission and for a pre-IND meeting with the FDA, we look forward to connecting with potential partners at BIO to explore licensing and M&A opportunities that can help accelerate our path to the clinic.'
Dr. Angel, Chief Scientific Advisor at Telomir, added:
'In all my years in drug development, I've never seen a molecule with this kind of cross-indication potential. The science behind Telomir-1 is remarkable-it's addressing cellular aging at its root, and the preclinical data speak for themselves. What excites me most is how this one molecule may have the power to transform how we treat aging-related, metabolic, and rare genetic diseases across the board.'
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
[email protected]
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
BF-A, BF-B Investors Have Opportunity to Join Brown-Forman Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brown-Forman Corporation ('Brown-Forman' or 'the Company') (NYSE: BF-A, BF-B) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Brown-Forman reported its financial results for fiscal year 2025 on June 5, 2025. The Company reported a decline in year-over-year sales of 7.3% and earnings per share below consensus estimates. The Company stated its "results did not meet our long-term growth aspirations," and advised investors that "looking ahead to fiscal 2026, we expect continued headwinds." If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
an hour ago
- Yahoo
Why Braze, Inc. (BRZE) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Braze, Inc. (NASDAQ:BRZE) stands against other Friday's worst-performing stocks. Braze Inc. dropped its share prices by 17.65 percent on Friday to finish at $29.73 apiece as investors soured on its dismal earnings performance in the first quarter of fiscal year 2026. In a statement, Braze, Inc. (NASDAQ:BRZE) said attributable net loss was unchanged at $35 million, despite revenues increasing by 20 percent to $162 million from $135 million, driven primarily by new customers, upsells, and renewals. A web developer hunched over their laptop coding a customer engagement platform. For the second quarter of the year, Braze, Inc. (NASDAQ:BRZE) is targeting to hit $171 million to $172 million in revenues, with a net income ranging from $2.5 million to $3.5 million. The full-year period alone is expected to rake in between $702 million and $706 million in revenues, and a net income of $17 million to $21 million. The company also welcomed Ed McDonnell as its new chief revenue officer. 'McDonnell has a strong track record of delivering results at high-growth public SaaS businesses, and we believe his extensive background in Software and Customer Engagement will further solidify Braze as the leading customer engagement platform and accelerate growth in the coming years,' said Braze, Inc. (NASDAQ:BRZE) CEO Bill Magnuson. Overall, BRZE ranks 3rd on our list of Friday's worst-performing stocks. While we acknowledge the potential of BRZE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why DocuSign, Inc. (DOCU) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where DocuSign, Inc. (NASDAQ:DOCU) stands against other Friday's worst-performing stocks. DocuSign dropped its share prices by 18.97 percent on Friday to end at $75.28 apiece after slashing its full-year billing outlook amidst its shift to an artificial intelligence model. For the full year period, DocuSign, Inc. (NASDAQ:DOCU) now expects billings to settle in the range of $3.285 billion to $3.339 billion, down from its previous outlook of $3.30 billion to $3.354 billion. A software engineer in front of a computer screen, typing code to build the company's electronic signature software. According to DocuSign, Inc. (NASDAQ:DOCU) CEO Allan Thygesen, the decline in billings this year was expected due to 'foundational go-to-market changes' following the adoption of Intelligent Agreement Management, an AI-driven agreement platform. However, Thygesen said that 'the impact happened sooner than anticipated,' causing the drop in early renewals during the first quarter period, and negatively impacting billings growth. In the first quarter of the year, DocuSign, Inc. (NASDAQ:DOCU) achieved a 118-percent jump in net income to $72 million from $33 million in the same period last year. Revenues increased by 7.6 percent to $763 million from $709 million year-on-year. Overall, DOCU ranks 2nd on our list of Friday's worst-performing stocks. While we acknowledge the potential of DOCU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
